Skip to main content

Table 4 Summary statistics for secondary efficacy variables

From: Evaluation of injectable robenacoxib for the treatment of post-operative pain in cats: results of a randomized, masked, placebo-controlled clinical trial

Group

Time

N

Posture score

Behavior viewed from a distance score

Behavior following social interaction score

Paw pain on palpation score

Soft tissue incision site pain on palpation score

Overall pain control score

Mean (SD)

P value

Mean (SD)

P value

Mean (SD)

P value

Mean (SD)

P value

Mean (SD)

P value

Mean (SD)

P value

Robenacoxib

0

175

3.72 (0.83)

0.85

1.18 (0.51)

0.95

1.99 (1.19)

0.78

4.82 (0.49)

0.72

1.06 (0.27)

0.51

1.11 (0.35)

0.75

Placebo

173

3.70 (0.89)

1.17 (0.51)

1.97 (1.21)

4.86 (0.41)

1.02 (0.15)

1.09 (0.32)

Robenacoxib

30 min

175

3.06 (1.06)

0.54

1.31 (0.55)

0.19

1.92 (1.04)

0.26

4.39 (0.96)

0.12

1.24 (0.55)

0.60

1.36 (0.56)

0.12

Placebo

173

2.99 (1.12)

1.23 (0.49)

1.80 (0.93)

4.56 (0.68)

1.21 (0.43)

1.25 (0.50

Robenacoxib

1 h

175

2.65 (1.16)

0.24

1.35 (0.56)

0.049

1.88 (0.95)

0.042

4.19 (1.08)

0.052

1.37 (0.59)

0.0067

1.50 (0.65)

0.0050

Placebo

173

2.52 (1.18)

1.24 (0.49)

1.67 (0.89)

4.40 (0.93)

1.20 (0.47)

1.31 (0.59)

Robenacoxib

3 h

175

2.32 (1.15)

0.0022

1.43 (0.61)

0.0086

1.81 (0.92)

0.0079

3.73 (1.27)

<0.0001

1.53 (0.73)

0.0001

1.66 (0.75)

<0.0001

Placebo

173

1.98 (1.07

1.27 (0.53)

1.53 (0.84)

4.22 (0.96)

1.30 (0.52)

1.37 (0.65)

Robenacoxib

5 h

175

2.21 (1.07)

0.0001

1.49 (0.66)

0.0001

1.83 (0.94)

0.0011

3.57 (1.37)

<0.0001

1.60 (0.76)

0.0076

1.78 (0.82)

<0.0001

Placebo

173

1.78 (0.93)

1.26 (0.53)

1.50 (0.81)

4.02 (1.02)

1.44 (0.57)

1.43 (0.68)

Robenacoxib

8 h

175

2.10 (1.07)

0.0001

1.50 (0.68)

<0.0001

1.81 (0.93)

0.0006

3.52 (1.33)

0.0008

1.65 (0.75)

0.0017

1.83 (0.82)

<0.0001

Placebo

173

1.66 (0.87)

1.20 (0.51)

1.45 (0.77)

3.88 (1.06)

1.46 (0.60)

1.43 (0.67)

Robenacoxib

24 h

107

1.32 (0.61)

ND

1.07 (0.25)

ND

1.21 (0.49)

ND

4.11 (1.0)

ND

1.34 (0.58)

ND

1.18 (0.45)

ND

Placebo

146

1.36 (0.60)

1.05 (0.23)

1.25 (0.59)

3.99 (1.05)

1.39 (0.59)

1.22 (0.51)

Robenacoxib

28 h

104

1.36 (0.67)

ND

1.04 (0.19)

ND

1.13 (0.39)

ND

4.16 (0.92)

ND

1.33 (0.57)

ND

1.16 (0.37)

ND

Placebo

140

1.26 0.54

1.04 (0.19)

1.19 (0.46)

3.99 (0.92)

1.37 (0.55)

1.16 (0.39)

Robenacoxib

32 h

102

1.30 (0.63)

ND

1.02 (0.14)

ND

1.13 (0.36)

ND

4.14 (1.02)

ND

1.30 (0.56)

ND

1.13 (0.34)

ND

Placebo

139

1.24 (0.49)

1.02 (0.15)

1.17 (0.45)

4.01 (0.93)

1.37 (0.56)

1.17 (0.37)

Robenacoxib

48 h

102

1.23 (0.51)

ND

1.01 (0.10)

ND

1.10 (0.33)

ND

4.06 (0.98)

ND

1.26 (0.56)

ND

1.12 (0.32)

ND

Placebo

139

1.15 (0.38)

1.01 (0.12)

1.09 (0.36)

3.96 (0.95)

1.28 (0.50)

1.07 (0.26)

Robenacoxib

52 h

102

1.20 (0.47)

ND

1.01 (0.10)

ND

1.11 (0.34)

ND

4.11 (0.92)

ND

1.28 (0.55)

ND

1.10 (0.30)

ND

Placebo

139

1.12 (0.35)

1.02 (0.15)

1.09 (0.36)

4.07 (0.94)

1.27 (0.52)

1.06 (0.24)

  1. P values less than 0.05 are shown in bold. Statistical analyses were performed only on data from time 0 min through hour 8
  2. Last Observation Carried Forward (LOCF) was applied for secondary variables from 0 to 8 h for cats which received rescue therapy (but not for 24 to 52 h)
  3. ND not done